The US Supreme Court could revisit its landmark ruling in Wyeth v. Levine that FDA-approved labeling does not block individuals from filing personal injury suits against pharma companies under state law. Merck has asked the court to specify that a drug manufacturer cannot be subject to failure-to-warn claims about a risk associated with its product if it informs FDA about the risk and the agency rejects adding it to the drug's label.
In its Dec. 4 orders, the court invited the Solicitor General to convey the US government's views on Merck...





